找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Biologic Therapy for Psoriasis; Cutting Edge Treatme Nicholas Brownstone,Tina Bhutani,Wilson Liao Book 2022 The Editor(s) (if applicable) a

[复制链接]
楼主: Disaster
发表于 2025-3-25 06:06:56 | 显示全部楼层
https://doi.org/10.1007/978-3-642-36999-5 IL-17 antagonists have also shown sustained treatment responses and a quick onset of action. The high response rate seen in IL-17 inhibitors in the treatment of moderate-to-severe psoriasis underscores the importance of the IL-23/Th17 pathway in the pathogenesis of psoriasis.
发表于 2025-3-25 11:02:14 | 显示全部楼层
2523-8884 h.Examines the 11 FDA approved biologic agents currently on .Biologic therapy is a treatment that strives to modulate a patient‘s immune system to fight a given disease. In psoriasis, a skin disorder that is partly caused by a dysregulated immune system resulting in well-demarcated red areas of the
发表于 2025-3-25 15:09:20 | 显示全部楼层
Kinderallergologie in Klinik und Praxisused in psoriasis is presented. Finally, outcome measures in psoriasis clinical trials are also introduced with the goal of making it easier to interpret results from research and development of psoriasis biologic agents.
发表于 2025-3-25 16:04:44 | 显示全部楼层
Genetik, Epidemiologie und Prävention context of association between increased efficacy, infection, and malignancy. Delineation of the beneficial and deleterious effects of these medications fosters greater precision in appropriate regimen selection.
发表于 2025-3-25 23:04:30 | 显示全部楼层
Kinderallergologie in Klinik und Praxiso-severe disease. Recent data have shown that biologics offer a safe and effective option for children. Currently, etanercept, ustekinumab, ixekizumab, and secukinumab are approved by the Food and Drug Administration for treatment in children. Approach to the use of biologics for pediatric psoriasis is detailed in this chapter.
发表于 2025-3-26 02:57:37 | 显示全部楼层
发表于 2025-3-26 06:18:28 | 显示全部楼层
Introduction to Biologic Therapy for Psoriasis,used in psoriasis is presented. Finally, outcome measures in psoriasis clinical trials are also introduced with the goal of making it easier to interpret results from research and development of psoriasis biologic agents.
发表于 2025-3-26 09:15:40 | 显示全部楼层
TNF-Alpha Class of Biologic Agents in Psoriatic Disease, context of association between increased efficacy, infection, and malignancy. Delineation of the beneficial and deleterious effects of these medications fosters greater precision in appropriate regimen selection.
发表于 2025-3-26 13:07:54 | 显示全部楼层
发表于 2025-3-26 19:24:03 | 显示全部楼层
Special Site Psoriasis,r in patients’ quality of life, localization of psoriasis to specialized areas of the body can also cause stigmatization and physical and psychosocial burden. In this chapter, we will review treatment options for special sites of psoriasis, focusing on the efficacy and safety of biologic agents.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-22 10:46
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表